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Abstract
Manipulation of body weight set point may be an effective weight loss and maintenance strategy as the homeostatic
mechanism governing energy balance remains intact even in obese conditions and counters the effort to lose weight.
However, how the set point is determined is not well understood. We show that a single injection of rapamycin (RAP), an
mTOR inhibitor, is sufficient to shift the set point in rats. Intraperitoneal RAP decreased food intake and daily weight gain for
several days, but surprisingly, there was also a long-term reduction in body weight which lasted at least 10 weeks without
additional RAP injection. These effects were not due to malaise or glucose intolerance. Two RAP administrations with a two-
week interval had additive effects on body weight without desensitization and significantly reduced the white adipose
tissue weight. When challenged with food deprivation, vehicle and RAP-treated rats responded with rebound hyperphagia,
suggesting that RAP was not inhibiting compensatory responses to weight loss. Instead, RAP animals defended a lower
body weight achieved after RAP treatment. Decreased food intake and body weight were also seen with
intracerebroventricular injection of RAP, indicating that the RAP effect is at least partially mediated by the brain. In
summary, we found a novel effect of RAP that maintains lower body weight by shifting the set point long-term. Thus, RAP
and related compounds may be unique tools to investigate the mechanisms by which the defended level of body weight is
determined; such compounds may also be used to complement weight loss strategy.
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Introduction
The most common weight loss strategy is caloric restriction and
exercise, as obesity is typically due to chronic excess in caloric intake
over energy expenditure [1]. However, weight loss is strongly
countered by physiological compensatory responses that often defeat
attempts to stay on a diet regimen and maintain weight loss [2,3]. It
has been proposed that obesity is not a state where energy
homeostasis is dysregulated, but where the defended body weight
level, or set point, is shifted upwards [4]. This is a major obstacle that
needs to be overcome if obesity and overeating are to be contained.
Rapamycin (RAP) is an inhibitor of the mammalian target of
rapamycin (mTOR). mTOR is a highly conserved serine/
threonine kinase that is inhibited by energy deficiency but
activated by energy and nutrient signals to promote cell growth
through well described pathways (see [5] for recent review).
Inhibition of mTOR by daily RAP administration reduces both
food intake and body weight gain in free-feeding animals and
provides resistance to diet-induced obesity [6,7,8]. In hypotha-
lamic neurons that regulate energy balance and food intake,
mTOR has been shown to mediate the anorexic and orexigenic
effects of leptin and ghrelin, respectively. These effects can be
blocked by direct injections of RAP into these areas [9,10,11].
Thus, peripherally administered RAP could exert actions either
peripherally or centrally, or both.
In the present study, we examined the effect of a single injection
of RAP (peripheral or central) on eating and body weight.
Consistent with chronic administration [6,7,8], acute RAP
produced a dose-dependent reduction in both food intake and
body weight gain. Unexpectedly, however, RAP treated animals
voluntarily maintained a lower body weight for weeks and months
in the absence of additional RAP administration. The persistent
lowered body weight by RAP could be explained by a sustained
downward shift in body weight set point or a disruption of
compensatory mechanisms for regaining body weight. Thus, the
goal of the current study was to test the hypothesis that acute RAP
causes a downward shift in body weight set point. Overall, our
findings suggest a novel role of mTOR in establishing a homeostatic
set point and that RAP may be a unique tool for probing the
determinants of body weight set point.
Methods
Animals
Male Sprague Dawley rats were obtained from the Vivarium at
Memorial University of Newfoundland at 7 weeks of age. The rats
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were housed individually in a temperature- and humidity-
controlled environment with a 12-h light/12-h dark cycle (lights
on at 7:00 am). Rats were given free access to a standard rodent
diet (Prolab RMH 3000: PMI Nutrition International LLC,
Brentwood, MO, USA) and water, unless otherwise stated. Body
weight and food intake were measured every 1–2 days unless
indicated otherwise at the same time each day (9:00–11:00 am).
Ethics Statement
All procedures involving animals adhered to the guidelines of
the Canadian Council on Animal Care, and were approved by the
Institutional Animal Care Committee of Memorial University.
Rapamycin injection
For intraperitoneal (i.p.) administration, rats received either
vehicle (VEH: 5% ethanol in 5% Tween 80 and 5% PEG 400 in
distilled water) or RAP (LC Laboratories, Woburn, MA, USA) in
vehicle at 0.1, 1, or 10 mg/kg, similar to [12,13].
For intracerebroventricular (i.c.v.) injection, rats were initially
implanted stereotaxically with guide cannulae aimed at the left
lateral ventricle under 4% chloral hydrate (400 mg/kg i.p.). After
16–19 days of recovery, rats received an i.c.v. injection of 1 mL of
DMSO as vehicle (VEH-ICV) or 50 mg of RAP in 1 mL DMSO
(RAP-ICV), similar to [9]. Upon completion of the experiment,
rats were anesthetized with 15% urethane and brains were
collected. To verify location of cannula tips, brains were sectioned
and stained with cresyl violet and examined microscopically.
Tracks formed by the guide cannulae reached the lateral ventricle
in all subjects.
Visceral Fat
Visceral fat was assessed in a sub-set of subjects that received 2
injections a week apart of VEH or RAP (RAP-RAP and VEH-
VEH groups). Rats were killed by CO2 inhalation approximately 2
weeks following the second injection. Retroperitoneal and
epididymal fat pads were dissected and weighed immediately to
determine total visceral fat mass.
Glucose Tolerance Test
Two groups of rats matched by weight were injected i.p. with
RAP (10 mg/kg) or VEH. Two weeks later, the rats were fasted
overnight for 16 hours. To establish basal values of blood glucose
(fasted), a drop of blood was drawn by nicking the tail vein with a
razor blade and glucose level in whole blood was measured with
Blood Glucose Monitoring System (Free Style Lite, Abbott). Then
the rats were injected with glucose solution (in H2O, 2 g/kg i.p.,
Time 0). Blood glucose levels were measured at 15, 30, 60, 90 and
120 minutes post-injection.
Conditioned Taste Aversion Test
All rats had unrestricted access to rodent chow and restricted
access to water (one hour each day, 9:00–10:00 am) for one week
(Days 1–7) prior to injection. Body weights were measured
approximately 2 hours later each day. On injection day (Day 8),
all rats were presented with one bottle containing 0.1% saccharin
in water for one hour (between 9:00–10:00 am). Immediately
following saccharin consumption, rats received an i.p. injection of
RAP (10 mg/kg), VEH, LiCl (as a positive control, dose of
127.17 mg/kg), or saline (vehicle for LiCl). The next day (Day 9),
the rats had 1-hour access to water. On Day 10, the rats were
given a 1-hour two-bottle preference test during which they had
access to a bottle containing 0.1% saccharin solution and another
bottle containing water. At 30 minutes into the test, the places of
bottles were exchanged to control for side preference effects.
Saccharin preference was calculated as a ratio of the total
amount of saccharin consumed during the one hour period to the
total amount of fluid (water + saccharin solution) consumed. A a
lower saccharin preference measure from controls indicates
whether the drug has produced a conditioned aversion to the
associated saccharin.
Yoke Procedure
Rats were divided into three groups having approximately equal
baseline food intake (differed by less than 1 gram). Rats in two of
the groups were ranked by food intake from highest to lowest.
Pairs were formed by taking the two subjects with the highest food
intake, the two with the next highest food intake, and so forth.
Within each pair one animal was randomly assigned to the RAP
and the other to the yoked condition (YOKE). The third group
formed the VEH group. Following the five day baseline period,
rats were injected i.p. on Day 0 with RAP (10 mg/kg) or vehicle
(VEH and YOKE groups). During the yoked period, daily food
intake was determined for each rat in the RAP group and
expressed as a percentage of its averaged daily food intake during
the baseline period. Each day of the 5-day yoked period, yoked
rats were given a percentage of their daily baseline food intake
amount which corresponded to that of their RAP counterpart for
the preceding 24 hour period. Animals were then placed back on
ad lib food; daily food intake and body weight were measured for
an additional week.
Food deprivation
Rats were given either a RAP (10 mg/kg) or VEH injection i.p.,
and then 24 hours or 2 weeks later, food was restricted to 5 grams
for 24 hours. All rats were returned to ad libitum feeding following
deprivation for the remainder of the experiment. Water was
available ad libitum at all times.
Data analysis
All body weights were expressed as a percentage of injection day
(Day 0) body weight in order to adjust for individual differences in
absolute body weight. Food efficiency (FE) was calculated by
dividing body weight gain by food intake (FI) (both in grams) for
each 24 hour period. There were no pre-treatment differences
among the groups in weight gain, FI or FE in any of the
experiments. One-way ANOVAs with Tukey’s post hoc tests were
used to test for differences among three or more groups, whereas
unpaired t-test was used to compare two groups, as appropriate.
Two-way Mixed ANOVA was used to compare two or more
groups that were repeatedly measured to follow the time course.
Paired t-test was used for within-group comparisons. Data are
expressed as mean 6 S.E.M. p,0.05 was considered significant.
Results
Single injection of rapamycin inhibits food intake and
body weight gain
To examine the effect of acute RAP treatment on energy
balance, 40 male Sprague Dawley rats were given a single i.p.
injection of either 0 (vehicle, VEH), 0.1, 1.0 or 10 mg/kg of RAP
(n= 10 for each group). We found that food intake (FI) and food
efficiency (FE) were significantly reduced during the first 3–5 days
post-injection in a dose-dependent manner (Fig. 1A–D). The effect
of 10 mg/kg RAP on FI was observed as early as Day 1 post-
injection, while the response was delayed to the second day at
1 mg/kg. This was accompanied by a transient (2–3 days)
Rapamycin Decreases Defended Body Weight in Rats
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Figure 1. Single systemic injection of rapamycin induces prolonged decrease in body weight gain. A: Rapamycin (RAP) i.p. injection on
Day 0 (vertical broken line) induces a transient decrease in daily food intake. B: Three-day cumulative food intake (Day 1–3 post-injection) shows a
dose-dependent inhibition. C: RAP induces a transient decrease in food efficiency. D: Three-day cumulative food efficiency (Day 1–3) shows a dose-
dependent suppression. E: RAP induces a transient decrease in daily weight gain. For panel A, C and E, *p,0.001 for 10 mg/kg vs.VEH; **p,0.05 for 1
and 10 mg/kg vs. VEH; ***p,0.05 for all RAP doses vs.VEH (two-way Mixed-ANOVA). For panels B and D,##p,0.01,###p,0.001 (one-way ANOVA
with Tukey’s test). F: Cumulative body weight gain curve depicting that RAP injection results in a downward shift in body weight. The first 2 weeks
(box) is expanded and shown in the inset. The effect is dose-dependent. VEH vs.10 mg/kg, p,0.01 on Day 3–74; VEH vs. 1 mg/kg, p,0.01 on Day 2–
11, p,0.05 on Day 14 and 18; VEH vs. 0.1 mg/kg, not significant (two-way Mixed-ANOVA). G, H: Averaged daily water intake (H) and water intake
normalized to/body weight (G) shows no difference between RAP (10 mg/kg)-treated animals compared to VEH (two-way Mixed-ANOVA).
doi:10.1371/journal.pone.0093691.g001
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decrease in daily body weight gain, which subsequently returned
to baseline levels in all groups (Fig.1E). As a result, the difference
in cumulative body weight gain persisted for up to 14 and 74 days
for 1 mg/kg and 10 mg/kg, respectively (Fig.1F). Despite the
persistent decrease in body weight, there was no difference in fluid
intake across days (Fig. 1G, H) between VEH and RAP-treated
animals. These results indicate that single RAP injection dose
dependently induces sustained reduction in body weight.
Double rapamycin injections has additive effects on
energy balance and reduces fat mass
There are reports of resistance to RAP in other experimental
contexts [14]. Thus, we examined whether a RAP administration
(10 mg/kg, i.p.) would affect responses to a subsequent RAP
treatment. Rats received a pair of RAP or VEH i.p. injections
(n = 10 each) with a 2-week interval between injections. We found
that the two injections of RAP were equally effective in reducing
FI, FE and weight gain (Fig.2A–F). The VEH group showed a
tendency of lower weight gain and FE after the second injection
compared to the first, which may be due to age-dependent slowing
of the rate of weight gain (Fig.2B). In RAP treated animals (n = 6),
the white adipose tissues were significantly smaller than those of
VEH controls (n = 5) (Fig.2G, H), consistent with previous reports
showing decreased adiposity following chronic RAP administra-
tion [6,7]. These data suggest that the RAP effect does not
desensitize with intermittent injections, at least when injections are
separated by 2 weeks, and it effectively reduces adiposity.
Possible side effects of single RAP injection
Since chronic RAP administration is known to induce glucose
intolerance [6,15,16,17], we conducted a glucose tolerance test
two weeks after single injection of RAP (10 mg/kg i.p., n = 8) or
VEH (n= 7). There was no difference in the fasting blood glucose
or response to glucose challenge between the two groups (Fig.3A).
Furthermore, in a separate cohort of animals (n = 5 each), we
found no difference in non-fasting blood glucose levels at 2-week
post-injection (Fig.3B). Therefore, a single RAP injection does not
appear to influence glucose homeostasis long-term, unlike the
glucose tolerance that develops with daily administrations of RAP
over a 2-week period, as shown previously [6,15,16,17].
There is a possibility that the reduced eating from RAP could be
due, at least in part, to sickness induced by the drug. The typical
conditioned taste aversion (CTA) procedure provides a robust and
sensitive test of drug-induced sickness, where animals are allowed
to drink a novel-flavored solution following which they are injected
with a drug. If the drug induced sickness, the animals would show
a CTA later for that flavored solution. Rats were given 1 hour
access to a novel saccharin solution (0.1% in water) followed
immediately by either RAP (10 mg/kg i.p., n = 9) or VEH (n= 9).
A two-bottle choice test was administered 2 days later when the
rats were given simultaneous access to water and 0.1% saccharin
solution. The total fluid intake from saccharin solution and water
was greater in VEH than RAP rats (Fig. 4A). This is in contrast to
the lack of effect of RAP on water intake (Fig. 1G, H), which may
be due to the experimental condition of the CTA test, involving
restricted fluid access and a choice of water and saccharin solution.
Saccharin preference was calculated as the proportion of saccharin
solution intake over total fluid intake. This test indicated no
differences in saccharin preference between RAP and VEH
treated rats (Fig.4B). In contrast, LiCl (i.p., n = 5) induced a robust
decrease in saccharin preference compared to saline injection
(n= 5; Fig. 4D), as expected [9]. Thus there was no evidence that
RAP induced CTA, which suggests that RAP-induced anorexia is
not due to illness.
Rapamycin lowers the defended level of body weight
Normally, caloric restriction and/or weight loss are followed by
rebound hyperphagia and increased efficiency in food storage.
However, RAP-treated animals did not display hyperphagia and
body weight remained lower than controls following the acute
Figure 2. Spaced injections of rapamycin have additive effect on body weight gain. A–C: A, C and E: Body weight gain (A), daily food
intake (C) and food efficiency (E) of rats given two i.p. injections (broken lines, Day 0 and 14) of RAP (10 mg/kg each) or VEH with a 2-week interval. #
p,0.05,## p,0.01,### p,0.001, VEH vs. RAP (two-way Mixed-ANOVA). Horizontal bars indicate the days when significance was seen. B, D and F:
Cumulative body weight gain, food intake and food efficiency during the first three days post-injection. ***p,0.001, VEH vs. RAP. There was no
statistical difference between two injections within the group (VEH1 vs. VEH2, RAP1 vs. RAP2) (two-way Mixed-ANOVA). G: The weight of white
adipose tissues (WAT), epididymal and retroperitoneal pads, in rats treated twice with VEH or RAP. H: WAT weight normalized to the body weight of
individual rat. # p,0.05, ### p,0.001 (unpaired t-test).
doi:10.1371/journal.pone.0093691.g002
Figure 3. Rapamycin does not affect glucose tolerance. A: There were no differences in blood glucose levels measured at 15, 30, 60, 90 and
120 minutes post-glucose injection in RAP and VEH animals (two-way Mixed-ANOVA). B: There is no difference in non-fasted blood glucose in rats
administered with VEH or RAP (10 mg/kg i.p.) at 2 weeks post-injection (unpaired t-test).
doi:10.1371/journal.pone.0093691.g003
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anorexic phase. This may be explained by the RAP-induced
reduction in FI and body weight not being sufficient to engage
counter-regulatory responses. To test this idea, a group of rats
(YOKE) were pair-fed to match the daily FI of RAP-treated rats
for the 5-day period following injection, but otherwise fed ad
libitum. As expected, the RAP and YOKE groups had lower body
weight gain and FI during the pair-feeding period compared to
free-feeding VEH treated rats (n = 8 each, Fig.5A, B). RAP and
YOKE groups did not differ in body weight during this period (p.
0.05). However, the YOKE group displayed an immediate
rebound in FI and FE during the first day upon returning to
free-feeding following the yoked period (Fig.5B, C). This suggests
that the degree of anorexia and weight loss induced by RAP is
sufficient to activate a counter-regulatory response in non-RAP
treated animals.
Next, we sought to determine whether RAP prevented the
development of compensatory responses to transient reduction in
FI and weight. To do this, rats were treated i.p. with either RAP
(10 mg/kg) or VEH, and then challenged with 24 h-food
deprivation (FD), beginning at either 24 h or 2 weeks post-
injection (immediate or late FD, respectively). At 24 h, acute
effects of RAP are present, whereas at 2 weeks the acute effects
would have subsided and only long-term effect on body weight
remains. Immediate FD induced a transient drop in body weight
in both RAP and VEH groups (n = 10 each, Fig.6A). Upon re-
feeding, rats recovered their body weight. However, RAP rats
settled to a lower weight level than the VEH controls. Both groups
showed a significant increase in FI post-FD compared to their
respective pre-FD levels (p,0.001, paired t-test, Fig.6B). The
magnitude of the increase was similar between groups (VEH
12.261.1 g, RAP 10.661.7 g; p.0.05, unpaired t-test). FE was
also increased, although the RAP group showed a greater change
in FE compared to the VEH group due to reduced FE on Day 1
post-injection (i.e. the day before FD; Fig.6C).
When FD was imposed 2 weeks after injection (late FD), both
RAP and VEH groups showed a transient decrease in body weight
(n = 10 each, Fig.6D), which recovered at an identical rate (Fig.6D
Figure 4. Rapamycin does not induce malaise or illness. A:
During the two-bottle test, RAP group ingested significantly less fluid
(sum of water and 0.1% Saccharin solution). *p,0.05 (unpaired t-test).
B: There was no difference in saccharin preference (unpaired t-test). C:
During the two-bottle test, there was no difference in total fluid intake
in LiCl- and VEH-treated rats (sum of water and 0.1% Saccharin
solution). D: LiCl-treated rats showed a significantly lower saccharin
preference compared to VEH-treated rats. ****p,0.0001 (unpaired t-
test)
doi:10.1371/journal.pone.0093691.g004
Figure 5. Rats pair-fed with RAP-treated animals show
compensatory overfeeding and weight rebound. A: During the
pair-feeding (shaded area), YOKE and RAP groups had lower weight
gain compared to VEH group. YOKE group regained weight upon
returning to ad libitum feeding. B and C: YOKE group show a transient
increase in food intake (B) and efficiency (C) following pair-fed period.
*p,0.05, ***p,0.001 VEH vs. YOKE and RAP; iii p,0.001 YOKE vs. VEH
and RAP; ###p,0.001 RAP vs. VEH and YOKE;#p,0.05 VEH vs.RAP; ¥
p,0.05 all three groups are different from each other (two-way Mixed-
ANOVA).
doi:10.1371/journal.pone.0093691.g005
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inset). There was a transient increase in FI and FE during re-
feeding in both groups (Fig.6E, F). The increase in FI (pre- vs.
post-FD) was less pronounced in the RAP group (VEH
11.161.0 g, RAP 6.860.7 g, p,0.005, unpaired t-test), which is
likely due to the difference in absolute body weight, as there was
no difference in FI normalized to body weight (VEH
0.10060.002, RAP 0.09860.003, p.0.05, unpaired t-test). These
results strongly suggest that RAP-treated animals are capable of
activating compensatory mechanisms to defend their body weight
in response to acute perturbations, even during the early phase
post-injection when rats do not attempt to recover the weight loss
by RAP. Therefore, it appears that RAP does not simply inhibit FI
and FE, but rather lowers the defended level of body weight.
Intracerebroventricular rapamycin produces prolonged
weight reduction
To determine whether the effect of systemic RAP that we
observed was due to a central action, we conducted a central
injection study. RAP i.c.v. (n = 9) reduced the daily weight gain, FI
and FE transiently (Fig.7A,C,D) and cumulative weight gain for up
to 15 days compared to those that received equal volume (1 mL) of
VEH i.c.v. (n = 11) (Fig.7B). There was some delay in the effect;
suppression of FI and cumulative weight gain became significant
Figure 6. Rapamycin-treated animals defend lower body weight in response to acute perturbation in energy balance. A, B and C: Rats
were injected i.p. with RAP or VEH on Day 0 (broken line), and then 24 h later food deprived (FD) as indicated by shaded area. In both groups, FD
resulted in an immediate decline in body weight (A), followed by a transient increase in food intake (B) and food efficiency (C) upon refeeding. D, E
and F: Rats were injected i.p. with RAP or VEH, then 2 weeks later challenged with FD (shaded area). D inset: Recovery rate of body weight following
FD is identical. *p,0.05, **p,0.01, ***p,0.001 (two-way Mixed-ANOVA). Horizontal bars in panel A, B, D and E indicate statistical significance at all
time points labeled.
doi:10.1371/journal.pone.0093691.g006
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on Day 2 and Day 4 post-injection, respectively. This is similar to
the delayed response seen after 1 mg/kg i.p. injection. These
results suggest that the effect of RAP is at least partially mediated
by the brain.
Discussion
The present study shows that single injection of RAP induces a
transient decrease in FI, FE and daily weight gain lasting for
several days. Surprisingly, the lowered body weight persists for at
least 74 days. These effects are not likely due to malaise or illness,
as there was no evidence for conditioned taste aversion to RAP.
Once the transient effects subside and lower body weight is
attained, RAP treated animals do not compensate for the lost
weight, unlike pair-fed controls who overeat upon resuming ad-
libitum feeding and regain weight. Instead, the rate of weight gain,
FI and FE of RAP rats is restored after 3–5 days to the levels of
vehicle controls, suggesting that energy homeostasis is re-
established. Subsequently, the RAP-treated animals defend the
newly established lower body weight upon acute perturbations in
energy balance by adjusting FI and FE. Specifically, acute food
deprivation induces a similar rebound hyperphagia upon re-
feeding and an identical rate of body weight recovery in RAP and
vehicle-treated groups. When food deprivation is applied within
the first few days following RAP injection during the transient
suppression of FI, rats are still able to respond with rebound
hyperphagia. This indicates that the lack of hyperphagia following
RAP is not due to a RAP-induced failure to activate counter-
regulatory responses. Also this supports our contention that
anorexia did not result from illness, as these animals are capable
of eating as much as pre-injection levels. Taken together, our data
indicate that RAP induces a downward shift in body weight set
point, and that the initial transient decrease in FI and FE following
injection is a compensatory response to the disparity between the
actual body weight and lowered set point. Therefore, our study
shows a novel effect of RAP on body weight regulation.
While peripheral action cannot be ruled out, our findings
strongly suggest that RAP acts centrally to exert its effect on
energy homeostasis. It is known that peripherally administered
RAP readily enters the brain [18] and inhibits p70S6K
phosphorylation, a downstream substrate of mTOR signaling
[19]. While the highest dose tested in our study (10 mg/kg) is
higher than those of previous food and body weight studies (0.2–
5 mg/kg/day) [6,7,8,10,20], 1 mg/kg in our study also produced
a significant effect on long-term weight gain. Also, the highest dose
used here is well below the RAP doses (e.g. 40 mg/kg) that are
effective in other experimental contexts such as fear conditioning
[12]. The elimination half-life of RAP is relatively long (approx-
imately 30 hours in rats [21]), however, this would not appear to
be of sufficient duration to suppress its target molecule for the
entire 10-week observation period in the present study. Therefore,
it is likely that a transient action of RAP is enough to induce a
long-lasting change in the neural circuitry for body weight
regulation. This may involve cap-dependent translation regulated
by mTOR, which has been implicated in synaptic plasticity [22].
It is well established that mTOR plays an important role in the
control of FI. Metabolic signals such as leptin and branched-chain
amino acids (e.g., leucine) activate mTOR1 to inhibit FI [9].
Accordingly, a single central injection of RAP has been shown to
increase FI transiently in sated rats by acting in the arcuate nucleus
and nucleus of the solitary tract in the hypothalamus and
brainstem, respectively [9,23]. This hyperphagic effect is short-
Figure 7. Rapamycin acts in the brain to decrease body weight gain. A and B: RAP i.c.v. injection (Day 0, broken line) induces a transient
decrease in body weight gain (A), which results in prolonged shift in body weight (B). C: Food intake is inhibited by RAP i.c.v. D: Food efficiency is
inhibited by RAP i.c.v. *p,0.05, **p,0.01, ***p,0.001 (two-way Mixed-ANOVA).
doi:10.1371/journal.pone.0093691.g007
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lived; it gradually diminishes with time within the first day post-
injection. We did not observe any increase in FI following systemic
or central injection of RAP, which may be because our earliest
time point was 24 h post-injection. The response we observed was
delayed by one day in rats treated with 1 mg/kg i.p. or 50 mg
i.c.v., which may be explained by hyperphagic and hypophagic
responses balancing out during the first 24 h. Alternatively, the
discrepancy may arise from the differences in feeding protocol.
Previous studies induced satiation prior to RAP injection by
overnight fast followed by re-feeding [23] or exposure to palatable
food [9]. Under such conditions, neurons that mediate satiety may
be fully activated and cannot be stimulated further. Another
possibility is an involvement of a mechanism recruited by
orexigenic factors such as ghrelin and thyroid hormone, which
activates mTOR pathway and agouti related protein/neuropep-
tide Y neurons in the hypothalamus to induce FI [11,24]. Single
central injection of RAP is sufficient to block the orexigenic effect
of ghrelin [11]. Overall, these contrasting effects of mTOR and
RAP on FI may involve different brain regions and/or neuronal
populations [11,25].
Chronic RAP administration (daily injections) also has mixed
effects on FI, which seems to depend on animal species, age, diet
and duration of RAP treatment, although weight gain is
consistently inhibited [6,7,8,10,20]. In aged mice, mTOR
promotes positive energy balance by negatively regulating the
activity of POMC neurons in the arcuate nucleus, which is
reversed by chronic RAP, suggesting an important role of POMC
neurons in the central RAP effect, at least with chronic
administration [10]. It is likely that at least some of the known
effects of chronic RAP treatment overlap with those seen in our
acute injection study, and reduced body weight may not be readily
reversible even when the RAP treatment is terminated.
Manipulation of set point would be an effective weight loss and
maintenance strategy, as deviating from the set point normally
results in strong activation of physiological compensatory mech-
anisms. We showed that acute injection of RAP, which
presumably induces a transient suppression of mTOR, can have
a long-lasting effect on the set point for body weight, suggesting a
novel role of mTOR in body weight regulation. Moreover, a single
injection has distinct advantage as it can avoid side effects of
chronic RAP administration such as glucose intolerance. We
propose that RAP and related compounds could be used as tools to
investigate how the defended level (apparent set point) of body
weight is determined and to complement other weight loss
strategies.
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